DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability ofDAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of

Antibodies Inc. Launches Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) for Reproducible Retinal Research

Okuma süresi: 2 dk

DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of its Recombinant Guinea Pig RBPMS Antibody (Clone OTI3B7-GP, Cat. No. 1834-RBPMS)—a next-generation antibody designed to deliver superior reproducibility, specificity, and performance in retinal ganglion cell (RGC) research.

Developed under the PhosphoSolutions brand, the recombinant Guinea Pig RBPMS Antibody continues a legacy of high-performance neuroscience reagents while benefiting from Antibodies Inc.’s expanded validation, manufacturing, and global distribution infrastructure. This new recombinant mAb replaces the formerly available guinea pig polyclonal RBPMS Antibody (Cat. No. 1832-RBPMS).

RBPMS (RNA Binding Protein with Multiple Splicing) has emerged as the gold-standard marker for identifying retinal ganglion cells, supporting accurate cell identification and quantification in vision and neurodegeneration research. While guinea pig polyclonal antibodies have historically been valuable for multiplex immunofluorescence, traditional formats are limited by lot-to-lot variability and finite supply.

Our Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) addresses these limitations through recombinant engineering, eliminating lot-to-lot variability and supply constraints. The antibody combines the well-validated antigen-binding region of the OTI3B7 clone with a guinea pig IgG constant region, enabling efficient multiplexing alongside mouse and rabbit antibodies while delivering long-term consistency.

Key benefits include:

  • Recombinant RBPMS Antibody for retinal ganglion cell identification
  • Guinea Pig format for advanced multiplex immunolabeling
  • Clone OTI3B7-GP with defined amino acid sequence
  • Animal-free, serum-free production
  • Lot-to-lot reproducibility for longitudinal and multi-site studies

The antibody has been validated for immunohistochemistry (IHC) and Western blotting, providing clear and specific labeling of retinal ganglion cells in mammalian tissue samples.

The launch further reflects Antibodies Inc.’s commitment to supporting scientific discovery through a growing portfolio of specialized research brands.

Related Resources:
Explore the full PhosphoSolutions product line:
https://www.antibodiesinc.com/collections/phosphosolutions

Recombinant Guinea Pig RBPMS Antibody Product page:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-recombinant-antibody-oti3b7-gp-1834-rbpms

Researchers seeking alternative host species can also access the Rabbit Polyclonal RBPMS Antibody:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-1830-rbpms

Learn more about the Antibodies Inc. family of brands:
https://www.antibodiesinc.com/pages/our-brands

Available Now
The Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP, 1834-RBPMS) is available now through Antibodies Inc. and authorized global distributors.

About Antibodies Inc.
Antibodies Inc. provides researchers worldwide with rigorously validated antibodies, recombinant proteins, ELISA kits, and custom services. Through a growing portfolio of specialized brands—including PhosphoSolutions—Antibodies Inc. delivers reproducible tools that accelerate discovery across neuroscience, cell biology, and translational research.

Cision View original content:https://www.prnewswire.com/news-releases/antibodies-inc-launches-recombinant-guinea-pig-rbpms-antibody-oti3b7-gp-for-reproducible-retinal-research-302666278.html

SOURCE Antibodies Inc.

Piyasa Fırsatı
Graphite Logosu
Graphite Fiyatı(GP)
$0.3207
$0.3207$0.3207
+3.92%
USD
Graphite (GP) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Paylaş
BitcoinEthereumNews2025/09/18 03:26
XRP Ledger Unlocks Permissioned Domains With 91% Validator Backing

XRP Ledger Unlocks Permissioned Domains With 91% Validator Backing

XRP Ledger activated XLS-80 after 91% validator approval, enabling permissioned domains for credential-gated use on the public XRPL. The XRP Ledger has activated
Paylaş
LiveBitcoinNews2026/02/06 13:00
XRPL Adds Institutional Lending and Privacy Tools in Ripple’s 2026 Roadmap

XRPL Adds Institutional Lending and Privacy Tools in Ripple’s 2026 Roadmap

Ripple shared a new Institutional DeFi roadmap showing how the XRP Ledger is being shaped for everyday use by banks, asset managers, and regulated financial firms
Paylaş
Tronweekly2026/02/06 13:00